Regenesis Biomedical

About Regenesis Biomedical

Regenesis Biomedical, established in 1996, is a privately held medical technology company focused on energy-based medical products for pain management. The company was founded by Dr. Frank George and Dr. Mary Ritz based on their Cell Proliferation Induction technology, which uses a physical stimulus to trigger cellular responses for regeneration. Dr. Ritz served as the company's President and CEO for over six years, securing significant early-stage funding and leading the company through initial clinical studies and FDA clearance for its first product.

The company's core product is the Provant® Therapy System, a non-invasive device that utilizes pulsed electromagnetic energy to alleviate post-operative pain and edema in soft tissues. This prescription-only system works by inducing the body's natural pain-relief mechanisms, including the release of endogenous opioids, and by regulating inflammatory mediators. The therapy is typically self-administered by the patient at home, with twice-daily, 30-minute treatments that are generally sensation-free. The Provant system is designed to be a non-narcotic alternative for pain management following various surgical procedures such as joint replacements, back surgery, and rotator cuff repair. In 2023, Regenesis received FDA clearance for its new Reprieve™ device, also based on its pulsed electromagnetic energy platform, which is intended for broader pain indications, including the pain associated with diabetic neuropathy, particularly targeting the Department of Veterans Health Administration (VA) market.

Regenesis Biomedical operates on a business-to-business-to-consumer model, selling its devices to healthcare facilities and providers. Its client base includes acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health agencies, and outpatient clinics. The company generates revenue through the sale and marketing of its energy-based medical devices. Several venture capital firms, including Solstice Capital, Valley Ventures, TGap Ventures, and Fulcrum Equity Partners, have invested in the company.